Conditions: Advanced Ovarian Carcinoma Primary Peritoneal Carcinoma Ovarian Carcinosarcoma
Keywords: Ovarian Cancer Gynecologic Cancer Ovarian Carcinoma Peritoneal Carcinoma IP chemotherapy Intraperitoneal Avastin Bevacizumab
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 20
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the tolerability of intraperitoneal cisplatin with intravenous paclitaxel and Avastin as defined by the proportion of patients able to complete 6 cycles of treatment.

Detailed description:
Ovarian cancer is the leading cause of death from gynecologic cancer in the United States. The high death rate stems from late presentation and tumor that has spread beyond the ovary at the time of diagnoses.

Ovarian cancer typically spreads throughout the peritoneal cavity. Three randomized clinical trial have recently demonstrated the superiority of intraperitoneal(IP) over intravenous platinum based chemotherapy in optimally debulked advance ovarian cancer. The success of Bevacizumab in metastatic colorectal cancer has led to trials evaluating its' efficacy in advanced ovarian cancer. Based on the mechanism of action of Bevacizumab, there may be benefit of extended therapy with this agent.

Arms:
arm 1: None

Interventions: intervention 1: Avastin intervention 2: Paclitaxel intervention 3: Cisplatin
Intervention descriptions: intervention 1: Initial Treatment Bevacizumab 15mg/kg Day 1 IV every 21 days x 5 cycles (beginning with cycle 2)

Consolidation Treatment:

Avastin 15mg/kg IV every 21 days x 12 cycles intervention 2: Paclitaxel 135mg/m2 IV Day 1 every 21 days x 6 cycles intervention 3: 75mg/m2 IP day 2 every 21 days x 6 cycles

Protocol document: